Noven Announces Results of 2009 Annual Meeting of Stockholders

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the results of its 2009 Annual Meeting of Stockholders. At the meeting, held earlier today, stockholders elected the following persons to Noven’s Board of Directors:

  • Peter Brandt – Noven’s President and CEO;
  • John G. Clarkson, M.D. – Executive Director of the American Board of Ophthalmology and Dean Emeritus and Professor of Ophthalmology, University of Miami Miller School of Medicine;
  • Donald A. Denkhaus – Executive Chairman, TM Systems, LLC and former partner with Arthur Andersen LLP;
  • Pedro P. Granadillo – Former Senior Vice President – Global Manufacturing and Human Resources, Eli Lilly & Company;
  • Phillip M. Satow – Former CEO and co-founder of JDS Pharmaceuticals, LLC;
  • Robert G. Savage – Former Worldwide Chairman, Pharmaceuticals Group, Johnson & Johnson; and
  • Wayne P. Yetter – Former CEO, Verispan LLC, and non-executive Chairman of the Board of Noven.

Stockholders also approved Noven’s 2009 Equity Incentive Plan and ratified the appointment of Deloitte & Touche LLP as Noven’s independent registered public accounting firm for 2009. At the meeting, Peter Brandt provided an update on Noven’s business and prospects, and a webcast of this presentation and the meeting proceedings will be available at for at least two weeks.

As announced in a May 15, 2009 press release, the appointment of Francois Nader, M.D., to the Noven Board became effective after the meeting. Dr. Nader is President and CEO of NPS Pharmaceuticals, Inc.

About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s business and operations are focused in three principal areas – transdermal drug delivery, the Novogyne Pharmaceuticals joint venture, and Noven Therapeutics, Noven’s specialty pharmaceutical marketing and sales unit. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. For more information, visit

Joseph C. Jones
Vice President – Corporate Affairs